Hearts & Minds Blog

Validating Our Approach: Dr. Ference to Present Results from Mendelian Randomization Studies of ACL Inhibition at the Upcoming ACC Scientific Session

Tim Mayleben

President and Chief Executive Officer

As a team of lipid management experts, we often “geek out” on the science behind LDL-cholesterol lowering therapies. That’s why we are particularly excited about this morning’s announcement regarding data from the new Mendelian randomization studies of ATP Citrate Lyase (ACL) inhibition, the target enzyme of bempedoic acid (Genetic Target Validation for ATP-Citrate Lyase Inhibition), which helps to further validate our therapeutic approach.

We partnered with Dr. Brian Ference, a leading authority in Mendelian randomization techniques on these critical studies in which we sought to determine whether LDL-cholesterol lowering via ACL resulted in a reduction in the risk for cardiovascular disease. After thorough research and data analysis, Dr. Ference concluded that bempedoic acid should reduce the risk of cardiovascular events by the same magnitude as statins, PCSK9 inhibitors and ezetimibe.

Dr. Ference will present findings from these studies at the American College of Cardiology (ACC) Scientific Session on Sunday, March 19, and again at a webcast to be held later that evening (view event details in our press release). We expect these results to be published in a top-tier medical journal later this year.

Our team is energized by these findings, which support the use of ACL inhibition in reducing elevated LDL-cholesterol levels and potentially the risk of cardiovascular events. Our CLEAR Outcomes cardiovascular outcomes trial (CVOT) was recently initiated to determine the ability of bempedoic acid to reduce the risk of cardiovascular events in statin intolerant patients. Dr. Ference’s work represents an encouraging and important milestone for bempedoic acid and Esperion.

We remain steadfastly focused on our mission to develop complementary, convenient and cost-effective oral therapies to treat patients with elevated LDL-cholesterol, and are enormously pleased to have this positive momentum as we forge ahead with our global pivotal Phase 3 program and CLEAR Outcomes CVOT.